NNM Securities

COMPANY
more from company profile
HomeMarket Info Company Profile Smart Quotes

Smart Quotes

JUBILANT PHARMOVA LTD.

NSE : JUBLPHARMABSE : 530019ISIN CODE : INE700A01033Industry : Pharmaceuticals & DrugsHouse : Jubilant Bhartia
BSE680.704.05 (+0.6 %)
PREV CLOSE ( ) 676.65
OPEN PRICE ( ) 689.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 13544
TODAY'S LOW / HIGH ( )676.60 689.90
52 WK LOW / HIGH ( )300.45 724
NSE680.652.85 (+0.42 %)
PREV CLOSE( ) 677.80
OPEN PRICE ( ) 680.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 680.65 (140)
VOLUME 238359
TODAY'S LOW / HIGH( ) 676.00 689.80
52 WK LOW / HIGH ( )300 724.4
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 21-06 1978
Management Info
Shyam S Bhartia - Chairman Priyavrat Bhartia - Managing Director
Registered Office

Address Bhartiagram ,Jyotiba Phoolay Nagar, ,
Gajraula,
Uttar Pradesh-244223

Phone 05924-267437

Email invstors@jubl.com

Website www.jubilantpharmova.com

Registrars Details
Alankit Assignments Ltd.
205-208 , Anarkali Complex,Jhandewala Extension,,New Delhi
 Listing : BSE, NSE, MCX
NEWS
25Apr USFDA concludes audit at Radiopharmace
United States Food and Drug Administration (USFDA) has concluded its aud..
18Apr Jubilant Pharmova informs about closur
Jubilant Pharmova has informed that the Company’s subsidiary Jubilant Ca..
30Mar Jubilant Pharmova informs about update
Jubilant Pharmova has informed that in continuation to earlier letter da..
26Mar Jubilant Pharmova informs about change
Pursuant to Regulation 30 of the SEBI Listing Regulations, Jubilant Phar..
11Mar Jubilant Pharmova informs about analys
In reference to its disclosure dated March 05, 2024 wherein the company..
MORE
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit-24498.8
Gross Profit -23 793.4
Operating Profit 1831411.1
Net Sales 17528101.2
MORE
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Divi's Lab (BSE)
 4025.35 (4.81%)
M.Cap (Rs. in Cr)106860.39
Sanofi India (BSE)
 8278.10 (1.76%)
M.Cap (Rs. in Cr)19064.98
Abbott India (BSE)
 25864.85 (0.54%)
M.Cap (Rs. in Cr)54961.00
Astrazeneca Pharma I (BSE)
 5415.40 (2.18%)
M.Cap (Rs. in Cr)13538.50
Glaxosmithkline Phar (BSE)
 2132.75 (3.26%)
M.Cap (Rs. in Cr)36130.07
MORE
Shareholding Pattern
PROMOTERS 50.68%
NON-INSTITUTION 26.49%
MUTUAL FUNDS/UTI 2.27%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%
MORE
Mf Holdings
MORE
ATTENTION INVESTORSKYCIPO
TERMS & CONDITIONS| PRIVACY POLICY| REFUND & CANCELLATION POLICY| DISCLAIMER| DISCLOSURE| KMP DETAILS | CDSL e-Voting | SEBI| FMC| NSE| BSE| MCX | SCORES
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
Assamese Bengali Gujrati Hindi Kanada
Kashmiri Konkani Malyalam Marathi Oriya
Punjabi Sindhi Tamil Telegu Urdu
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
SMART ODR Portal
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.